Intel Corporation (INTC), Bristol Myers Squibb Co. (BMY): Three Noteworthy Upgrades Worth a Look

While I appreciate Barclay’s channel check and the bullish price target on a stock that I own, I can’t help but think that Barclay’s is late to the party. With that said, I am extremely bullish on the outlook for Sodastream International Ltd (NASDAQ:SODA), believing the company’s 1% presence in the U.S. could triple. However, I always find it a bit irresponsible when a firm upgrades a stock with 130% annual gains that “was” trading with 50% growth at 20 times earnings. Thus, I don’t like the timing of this call – but I agree with the price target – I think $100 is possible.

Final thoughts

When I look at the three noted upgrades above, I think Bristol-Myers is presenting the best opportunity.

Intel has traded flat for over a decade, and operates in a space that is highly volatile. Sodastream International Ltd (NASDAQ:SODA) is a personal favorite of mine — a company that has grown rapidly for four years — yet has significant short presence that could stop the stock from reaching such a bullish target.

With Bristol-Myers, the anti PD-1 market is potentially enormous. It is the next phase of immunotherapy, the process of blocking PD-1 to allow the immune system to effectively fight cancer. Most importantly, these drugs are working, and Bristol-Myers is ahead of all competition.

In biotechnology, you rarely see technology of this caliber that revolutionizes an industry – but Bristol Myers Squibb Co. (NYSE:BMY) has this asset – and could benefit greatly in the years ahead with a best-selling line of products.

Brian Nichols is long SODA. The Motley Fool recommends Intel and SodaStream. The Motley Fool owns shares of Intel and SodaStream. Brian is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article 3 Noteworthy Upgrades Worth a Look originally appeared on Fool.com is written by Brian Nichols.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.